Search

Your search keyword '"V. Heu"' showing total 2 results
Start Over Author "V. Heu" Topic anti-obesity agents
2 results on '"V. Heu"'

1. A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity.

Author

Weghuber D, Forslund A, Ahlström H, Alderborn A, Bergström K, Brunner S, Cadamuro J, Ciba I, Dahlbom M, Heu V, Hofmann J, Kristinsson H, Kullberg J, Ladinger A, Lagler FB, Lidström M, Manell H, Meirik M, Mörwald K, Roomp K, Schneider R, Vilén H, Widhalm K, Zsoldos F, and Bergsten P

Subjects
Adolescent, Body Mass Index, Child, Double-Blind Method, Female, Glucose Tolerance Test, Humans, Male, Pediatric Obesity metabolism, Anti-Obesity Agents therapeutic use, Exenatide therapeutic use, Pediatric Obesity drug therapy
Abstract

Background: Pharmacological treatment options for adolescents with obesity are very limited. Glucagon-like-peptide-1 (GLP-1) receptor agonist could be a treatment option for adolescent obesity., Objective: To investigate the effect of exenatide extended release on body mass index (BMI)-SDS as primary outcome, and glucose metabolism, cardiometabolic risk factors, liver steatosis, and other BMI metrics as secondary outcomes, and its safety and tolerability in adolescents with obesity., Methods: Six-month, randomized, double-blinded, parallel, placebo-controlled clinical trial in patients (n = 44, 10-18 years, females n = 22) with BMI-SDS > 2.0 or age-adapted-BMI > 30 kg/m 2 according to WHO were included. Patients received lifestyle intervention and were randomized to exenatide extended release 2 mg (n = 22) or placebo (n = 22) subcutaneous injections given once weekly. Oral glucose tolerance tests (OGTT) were conducted at the beginning and end of the intervention., Results: Exenatide reduced (P < .05) BMI-SDS (-0.09; -0.18, 0.00), % BMI 95th percentile (-2.9%; -5.4, -0.3), weight (-3 kg; -5.8, -0.1), waist circumference (-3.2 cm; -5.8, -0.7), subcutaneous adipose tissue (-552 cm 3 ; -989, -114), 2-hour-glucose during OGTT (-15.3 mg/dL; -27.5, -3.1), total cholesterol (11.6 mg/dL; -21.7, -1.5), and BMI (-0.83 kg/m 2 ; -1.68, 0.01) without significant change in liver fat content (-1.36; -3.12, 0.4; P = .06) in comparison to placebo. Safety and tolerability profiles were comparable to placebo with the exception of mild adverse events being more frequent in exenatide-treated patients., Conclusions: Treatment of adolescents with severe obesity with extended-release exenatide is generally well tolerated and leads to a modest reduction in BMI metrics and improvement in glucose tolerance and cholesterol. The study indicates that the treatment provides additional beneficial effects beyond BMI reduction for the patient group., (© 2020 The Authors. Pediatric Obesity published by John Wiley & Sons Ltd on behalf of World Obesity Federation.)

Published
2020
Full Text
View/download PDF

2. A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity

Author

Reinhard Schneider, Iris Ciba, K. Bergström, Hjalti Kristinsson, Janne Cadamuro, Katharina Mörwald, Joel Kullberg, Hannes Manell, F. B. Lagler, Peter Bergsten, M. Meirik, A. Ladinger, Kirsten Roomp, Susanne M. Brunner, Anders Alderborn, Daniel Weghuber, Anders Forslund, V. Heu, Fanni Zsoldos, Håkan Ahlström, Marie Dahlbom, M. Lidström, Kurt Widhalm, H. Vilen, and J. Hofmann

Subjects
Male, 0301 basic medicine, Pediatric Obesity, medicine.medical_specialty, Adolescent, GLP-1 receptor agonist, exenatide, glucose metabolism, pediatric obesity, Placebo-controlled study, 030209 endocrinology & metabolism, Endocrinology and Diabetes, Placebo, Gastroenterology, Pediatrics, metabolic syndrome, Body Mass Index, liver steatosis, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Internal medicine, medicine, Humans, Child, Adverse effect, Body mass index, 2. Zero hunger, 030109 nutrition & dietetics, Nutrition and Dietetics, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Pediatrik, Glucose Tolerance Test, medicine.disease, 3. Good health, Clinical trial, Tolerability, Pediatrics, Perinatology and Child Health, Endokrinologi och diabetes, Exenatide, Female, Anti-Obesity Agents, Metabolic syndrome, business, medicine.drug
Abstract

BACKGROUND: Pharmacological treatment options for adolescents with obesity are very limited. Glucagon-like-peptide-1 (GLP-1) receptor agonist could be a treatment option for adolescent obesity. OBJECTIVE: To investigate the effect of exenatide extended release on body mass index (BMI)-SDS as primary outcome, and glucose metabolism, cardiometabolic risk factors, liver steatosis, and other BMI metrics as secondary outcomes, and its safety and tolerability in adolescents with obesity. METHODS: Six-month, randomized, double-blinded, parallel, placebo-controlled clinical trial in patients (n = 44, 10-18 years, females n = 22) with BMI-SDS > 2.0 or age-adapted-BMI > 30 kg/m2 according to WHO were included. Patients received lifestyle intervention and were randomized to exenatide extended release 2 mg (n = 22) or placebo (n = 22) subcutaneous injections given once weekly. Oral glucose tolerance tests (OGTT) were conducted at the beginning and end of the intervention. RESULTS: Exenatide reduced (P De två första författarna delar förstaförfattarskapet

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results